12 Defensive Healthcare Dividend Stocks To Buy

Published on December 12, 2022 at 12:48 pm by Vardah Gill in Dividend Stocks, Hedge Funds, News

In this article, we discuss 12 defensive healthcare dividend stocks to buy now. You can skip our detailed analysis of the healthcare sector and its performance over the years, and go directly to read 5 Defensive Healthcare Dividend Stocks to Buy.

People invest in dividend stocks for several reasons. One reason is that these stocks can provide a regular source of income in the form of dividends, which are payments made by the company to its shareholders. This can be especially appealing to investors who are looking for a way to generate a steady stream of income from their investments. Additionally, dividend stocks may be seen as a safer investment compared to other types of stocks, since companies that pay dividends are often more established and financially stable. This can provide investors with some peace of mind, knowing that their investment is less likely to be impacted by market volatility or other factors. Finally, many investors view dividend stocks as a good long-term investment, since they can provide both income and the potential for capital appreciation over time. Defensive stocks are those that hold up well during periods of economic downturns. The healthcare sector is considered one of the most reliable defensive industries because these companies benefit from growing consumer demand regardless of the overall economy.

The onset of the pandemic of 2020 has shifted the dynamics of the global healthcare system. The healthcare industry in the US is the biggest in the world, which accounted for over 17% of the national GDP in 2020, according to a report by Insider Intelligence. The report also referred to the data by Deloitte and mentioned that health spending in the US will reach $8.3 trillion by 2040, up from $4 trillion in 2020.

Over the years, the healthcare industry has generated solid revenues in the US. CNBC cited data from McKinsey & Company and mentioned that the sector’s earnings are projected to grow 6% annually from 2021 through 2025, producing an additional $31 billion in profits. The same report mentioned that various healthcare companies in the US have given positive growth outlooks for the next few years. This year’s economic chaos also couldn’t target the sector as harshly as other industries. The S&P 500 Health Care index is down by 2.36% year-to-date, versus a 17.97% decline in the broader market, as of December 12. The index gained 9.6% in October, recording its best month since April 2020, as reported by Bloomberg. Another report by AllianceBernstein stated that healthcare stocks have significantly outperformed in down markets from 2000 through June 2022.

The solid performance of healthcare stocks can also be attributed to the fact that many health companies are dividend payers. Historically, dividend stocks have proved their mettle in periods of an economic clampdown. Companies like Exxon Mobil Corporation (NYSE:XOM), Kimberly-Clark Corporation (NYSE:KMB), and The Coca-Cola Company (NYSE:KO) gained investors’ attention due to their strong dividend growth track records and solid returns this year. In this article, we will further discuss defensive healthcare dividend stocks to buy.

Source: Unsplash

Our Methodology:

For this list, we selected healthcare stocks that pay regular dividends to shareholders. These companies have shown strong performance this year and have solid credentials. The stocks are ranked according to their dividend yields, as of December 12.

12. McKesson Corporation (NYSE:MCK)

Dividend Yield as of December 12: 0.58%

McKesson Corporation (NYSE:MCK) is a Texas-based company that distributes pharmaceuticals and provides healthcare management tools. In fiscal Q2 2023, the company reported revenue of $70.2 billion, which showed a 5.4% growth from the same period last year. For the first six months of the year, it generated over $166 million in operating cash flow. The company paid $139 million in dividends to shareholders during this period, which places it as one of the best dividend stocks on our list.

McKesson Corporation (NYSE:MCK) currently pays a quarterly dividend of $0.54 per share and has a dividend yield of 0.58%, as of December 12. The company has been raising its dividends consistently for the past six years. Its strong cash position makes it a good investment alongside other dividend stocks like Exxon Mobil Corporation (NYSE:XOM), Kimberly-Clark Corporation (NYSE:KMB), and The Coca-Cola Company (NYSE:KO).

Cowen appreciated the underlying business of McKesson Corporation (NYSE:MCK) in November and raised its price target on the stock to $416 with an Outperform rating on the shares.

At the end of Q3 2022, 51 hedge funds tracked by Insider Monkey owned stakes in McKesson Corporation (NYSE:MCK), up from 47 in the previous quarter. The collective value of these stakes is over $4.08 billion. With over 3 million shares, Berkshire Hathaway was the company’s leading stakeholder in Q3.

Baron Funds mentioned McKesson Corporation (NYSE:MCK) in its Q3 2022 investor letter. Here is what the firm has to say:

“McKesson Corporation (NYSE:MCK) is a leading distributor of pharmaceuticals and medical supplies. The company also provides prescription technology solutions that connect pharmacies, providers, payers, and biopharmaceutical customers. The stock price rose on solid financial results as its business is less exposed to current macroeconomic headwinds. We continue to have conviction that McKesson can grow earnings per share by an average of 12% to 14% annually and think the stock is still reasonably valued.”

11. Elevance Health Inc. (NYSE:ELV)

Dividend Yield as of December 12: 0.98%

Elevance Health Inc. (NYSE:ELV) is an American health insurance provider and also offers other medical services to its consumers. The company was previously operating as Anthem and changed its name to Elevance Health in June this year. It currently pays a quarterly dividend of $1.28 per share for a dividend yield of 0.98%, as of December 12. The company is one of the best dividend stocks on our list as it has raised its dividends for 11 years in a row.

In Q3 2022, Elevance Health Inc. (NYSE:ELV) generated $39.6 billion in revenues, up 11.5% from the same period last year. The company’s operating cash flow came in at $4.9 billion, an increase of $2.4 billion from the prior-year period. During the quarter, the company also paid $306 million to shareholders in dividends.

In October, UBS raised its price target on Elevance Health Inc. (NYSE:ELV) to $610 with a Buy rating on the shares, following the company’s Q3 earnings. The firm also mentioned that the company’s commercial book is not seeing signs of a recession.

As of the close of Q3 2022, 71 hedge funds tracked by Insider Monkey owned stakes in Elevance Health Inc. (NYSE:ELV), with a total value of over $5.3 billion.

Vulcan Value Partners mentioned Elevance Health Inc. (NYSE:ELV) in its Q3 2022 investor letter. Here is what the firm has to say:

“We purchased Elevance Health Inc. (NYSE:ELV), formerly known as Anthem. We owned Anthem for many years, up until late last year, and we are excited to own it again. The healthcare industry is complex, but we believe Elevance is well positioned to weather those challenges. Elevance is the largest healthcare insurance company in United States by medical membership, covering 47 million lives – 2/3rds of which are covered under commercial and specialty arrangements, and the other 1/3rd under government programs such as Medicare and Medicaid. The managed care industry is large, with healthcare spending of $4 trillion annually, and we believe that scale combined with expertise are important for success in this industry. We think that Elevance is one of a few large players who bring those strengths to bear. We estimate that Elevance will generate operating revenue north of $150 billion this year. Their size and scale allow for significant investments in technology and benefit design. We think that Elevance has good momentum and estimate that it should be able to grow its free-cash-flow per share at healthy rates despite the economy’s challenges.”

10. Eli Lilly and Company (NYSE:LLY)

Dividend Yield as of December 12: 1.09%

Eli Lilly and Company (NYSE:LLY) is a multinational pharmaceutical company that distributes its products to over 125 countries. In December, UBS raised its price target on the stock to $428 with a Buy rating on the shares, highlighting the company’s overall performance and its guidance for the full year.

Eli Lilly and Company (NYSE:LLY) holds one of the longest dividend records, paying regular dividends to shareholders since 1885. Moreover, it has raised its payouts consistently for the past eight years, which makes it one of the best dividend stocks on our list. The company currently offers a quarterly dividend of $0.98 per share and has a dividend yield of 1.09%, as of December 12.

Since the beginning of this year, Eli Lilly and Company (NYSE:LLY) returned 32.8% to shareholders, and its 12-month returns stood at 45.2%, as recorded on December 12.

At the end of September, 75 hedge funds in Insider Monkey’s database owned stakes in Eli Lilly and Company (NYSE:LLY), growing from 70 in the previous quarter. These stakes have a collective value of over $5.4 billion. With nearly 4 million shares, Fisher Asset Management was the company’s leading stakeholder.

ClearBridge Investments mentioned Eli Lilly and Company (NYSE:LLY) in its Q3 2022 investor letter. Here is what the firm has to say:

“In the U.S., we initiated a position in pharmaceutical maker Eli Lilly (NYSE:LLY) as it brings out new drug candidates for diabetes and Alzheimer’s disease. New drugs impact diabetes but have also demonstrated significant weight loss for patients who are overweight and have other co-morbidity issues as a result. Lilly is one of the two key players in diabetes care and we believe the potential market opportunity is much higher than the consensus forecasts as we are seeing evidence of accelerating adoption.”

9. UnitedHealth Group Incorporated (NYSE:UNH)

Dividend Yield as of December 12: 1.22%

UnitedHealth Group Incorporated (NYSE:UNH) is an American multinational healthcare and insurance company. In Q3 2022, the company reported an operating cash flow of $18.5 billion, and its adjusted free cash flow came in at $8.8 billion. In the first nine months of the year, it paid $10.5 billion to shareholders in dividends and share repurchases, coming through as one of the best dividend stocks.

UnitedHealth Group Incorporated (NYSE:UNH) has been making regular dividends to shareholders since 1990. It currently pays a quarterly dividend of $1.65 per share for a dividend yield of 1.22%, as of December 12.

Credit Suisse analyst A. J. Rice lifted his price target on UnitedHealth Group Incorporated (NYSE:UNH) to $610 with an Outperform rating on the shares.

UnitedHealth Group Incorporated (NYSE:UNH) was one of the most popular stocks among hedge funds in Q3 2022, as 110 funds tracked by Insider Monkey had positions in the company, up from 91 in the previous quarter. These stakes are collectively valued at over $10.3 billion.

Aristotle Atlantic Partners, LLC mentioned UnitedHealth Group Incorporated (NYSE:UNH) in its Q3 2022 investor letter. Here is what the firm has to say:

“UnitedHealth Group Incorporated (NYSE:UNH) is a leading U.S. health insurer offering a variety of plans and services to group and individual customers nationwide. Its health benefits segment manages health maintenance organization, preferred provider organization and point-of-service plans, as well as Medicare, Medicaid, state-funded, and supplemental vision and dental options. In addition, UnitedHealth Group’s Optum health services units—OptumHealth, OptumInsight and OptumRx—provide wellness and care management programs, financial services, information technology solutions, and pharmacy benefit management services to individuals and the health care industry. We believe UnitedHealth Group is well-positioned as a leader in commercial and government insurance markets with a broad complimentary service offering through Optum Health. As one of the largest health care payers and providers, we believe the company has unique insights and scale to continue to evolve the health care delivery process and drive above industry profitability and growth. We believe UnitedHealth Group’s track record of financial strength and stability warrants a premium in share valuation.”

8. Cigna Corporation (NYSE:CI)

Dividend Yield as of December 12: 1.35%

Cigna Corporation (NYSE:CI) is an insurance company that mainly provides healthcare insurance services to its consumers. In the past five years, the company has raised its dividend at a CAGR of 151.2% and its dividend growth streak currently stands at 2 years. It pays a quarterly dividend of $1.12 per share and has a dividend yield of 1.35%, as of December 12.

Since the start of the year, Cigna Corporation (NYSE:CI) delivered a 41.8% return to shareholders and its 12-month return came in at 54.3%, as of December 12.

In the third quarter of 2022, Cigna Corporation (NYSE:CI) reported revenue of $$45.2 billion, which showed a 2.2% growth from the same period last year. Its shareholders’ net income for the quarter came in at $2.8 billion and its adjusted income from operations stood at $1.9 billion.

In November, Morgan Stanley assumed its coverage on Cigna Corporation (NYSE:CI) with an Overweight rating and a $347 price target, up from $318. The firm mentioned that the company offers a ‘unique investment opportunity’ and appreciated its solid earnings.

The number of hedge funds tracked by Insider Monkey owning stakes in Cigna Corporation (NYSE:CI) jumped to 76 in Q3 2022, from 66 in the previous quarter. The collective value of these stakes is over $3.11 billion.

Aristotle Atlantic Partners, LLC mentioned Cigna Corporation (NYSE:CI) in its Q3 2022 investor letter. Here is what the firm has to say:

“Cigna Corporation (NYSE:CI) outperformed the S&P 500 Index in the third quarter, as the company reported what we view as solid second quarter results driven by a better-than-expected medical loss ratio. The company continues to be aggressive with share repurchases and we believe the defensive nature of Cigna’s business continues to be attractive during the ongoing macroeconomic uncertainty.”

7. CVS Health Corporation (NYSE:CVS)

Dividend Yield as of December 12: 2.16%

CVS Health Corporation (NYSE:CVS) is an American healthcare company that owns retail pharmacies and also provides healthcare insurance services to its consumers. In Q3 2022, the company reported revenue of $81.2 billion, which showed a 10% growth from the same period last year. Year-to-date, the company generated $18.1 billion in operating cash flow. During the quarter, it paid $726 million to shareholders in dividends, which makes it one of the best dividend stocks on our list.

CVS Health Corporation (NYSE:CVS) currently offers a quarterly dividend of $0.55 per share and has a dividend yield of 2.16%, as of December 12.

Morgan Stanley initiated its coverage of CVS Health Corporation (NYSE:CVS) with an Overweight rating and a $119 price target, highlighting the company’s long-term performance.

At the end of Q3 2022, 67 hedge funds tracked by Insider Monkey owned stakes in CVS Health Corporation (NYSE:CVS), up from 65 in the previous quarter. These stakes have a consolidated value of $2.1 billion.

Vltava Fund mentioned CVS Health Corporation (NYSE:CVS) in its Q3 2022 investor letter. Here is what the firm has to say:

“CVS is a leader in the provision of healthcare services in the USA. It has three main businesses: an enormous network of pharmacies, a health insurance company, and “prescription benefit management”, which is a kind of intermediary between insurance companies and pharmacies. This is the result of large acquisitions over the past 15 years – most notably of Caremark (2007) and Aetna (2018). The markets had deemed its acquisition of health insurer Aetna too expensive (and we agree), so CVS stock then fell into disfavour for a few years.

We took advantage of this in the summer of 2020 and brought the stock into our portfolio at a time when its price was pressed down still further by the coronavirus pandemic. CVS is a giant. It has revenues of USD 300 billion, making it one of the largest companies in the world. It is a relatively stable and highly profitable company with strong free cash flow. Over the past few years, CVS has focused primarily on reducing debt.

This is already much lower than it had been after the Aetna acquisition, and most of the cash is now likely to go to shareholders through share buybacks or be used for smaller acquisitions to grow the company further. CVS trades at about 11 times annual earnings, which is a very appealing valuation given the expected future growth in profitability and overall modest cyclicality in its business.”

6. Cardinal Health, Inc. (NYSE:CAH)

Dividend Yield as of December 12: 2.56%

Cardinal Health, Inc. (NYSE:CAH) provides cost-effective treatments to its consumers and also deals in other medical products. In November, Credit Suisse raised its price target on the stock to $79 with a Neutral rating on the shares, appreciating the company’s performance and balance sheet.

In fiscal Q1 2023, Cardinal Health, Inc. (NYSE:CAH) generated $49.6 billion in revenues, up 13% from the same period last year. The company had $3.5 billion available in cash and cash equivalents at the end of the quarter, and its total assets stood at over $43.3 billion.

Cardinal Health, Inc. (NYSE:CAH) is a Dividend Aristocrat as the company has been raising its dividends for the past 36 years. It currently pays a per-share dividend of $0.4957 every quarter. The stock’s dividend yield on December 12 came in at 2.56%. The company is a good addition to dividend portfolios alongside Exxon Mobil Corporation (NYSE:XOM), Kimberly-Clark Corporation (NYSE:KMB), and The Coca-Cola Company (NYSE:KO).

At the end of Q3 2022, 45 hedge funds in Insider Monkey’s database owned stakes in Cardinal Health, Inc. (NYSE:CAH), up from 44 a quarter earlier. The stakes owned by these hedge funds have a total value of over $1.03 billion.

Ariel Investments mentioned Cardinal Health, Inc. (NYSE:CAH) in its Q3 2022 investor letter. Here is what the firm has to say:

“Additionally, distributor of pharmaceutical and medical products Cardinal Health, Inc. (NYSE:CAH) advanced in the period as leadership changes were viewed to be a positive for shares. Management provided a new profit outlook for Fiscal 2023 and announced an improvement plan for the medical segment. We are encouraged by these changes and think CAH’s underlying fundamentals and competitive advantages around preventative maintenance screenings and medication management will continue to improve. We believe valuations of health care companies like CAH that focus on cost optimization and promote technological efficiency across the supply chain will be rewarded over the long term.”

Click to continue reading and see 5 Defensive Healthcare Dividend Stocks To Buy.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on October 30, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

Published on November 16, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up